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Introduction
One of the objectives in the development of gene therapy is to deliver the therapeutic gene to the relevant cell. For this purpose, two types of vectors are mainly being used. Nonviral vectors such as liposomes transport genes to the nucleus in a rather nonspecific way involving membrane association and endocytosis. In contrast, viral vectors exploit a 'natural' entry mechanism to deliver the gene to the nucleus efficiently. Retroviruses, vaccinia viruses and adenoviruses are the vectors used by most investigators. Each has advantages and disadvantages (for a review, see Ref. 1) , but in the context of pulmonary delivery, where multiplication of cells is not prominent, adenoviruses seem to be the most promising vectors since viral infection is not cell-replication dependent. Recently, replication-deficient adenovirus of serotype 5 (Ad-5) has been used by a growing number of investigators to administer an array of pro-and antiinflammatory genes to the lung in vivo. [2] [3] [4] [5] [6] The success of pulmonary gene therapy relies on different factors, among which the duration of expression of the relevant gene is of paramount importance. It has recently become apparent that the expression of adenovirus-driven genes (both quantitatively and temporally) is limited principally by the immune response mounted by the host. The immune reponse involves both cytotoxic CD8
+ cells and antibody forming B cells. 7 To circumvent this problem, two different types of approach are currently in favour: first, in order to ablate or diminish the cytotoxic CD8 + response directed towards de novo proteins (viral and recombinant), helper-dependent viruses have been constructed in which most or all of the viral genome has been deleted; [8] [9] second, blocking of the interaction between CD4
+ and B cells 10 and of the generation of neutralising IgA 11 have both recently been successful in allowing re-administration of virus.
In order to achieve high expression of transgene with the lowest possible viral load, it is important to find the optimal combination of vector and promoter driving the foreign gene. To this effect, this study set out to define an optimally efficient promoter system for expressing genes of interest. Indeed, few studies have compared the strength of various promoters, particularly in vivo.
In keeping with our interest in the potential use of elastase inhibitors as regulators of lung tissue damage and inflammation, we chose to insert the cDNA of a recently identified elastase inhibitor, elafin/elastase-specific inhibitor, [12] [13] [14] [15] [16] downstream of different promoters (human cytomegalovirus promoter (HCMV), Ad2 major late promoter (MLP), mouse cytomegalovirus promoter (MCMV)) and study the level of expression obtained both in vitro and in the lung of Sprague-Dawley rats.
Results
To identify promoters suitable for use in gene transfer and gene therapy, we have investigated the expression of elafin, a low molecular weight elastase inhibitor using several promoters in E1-substituted adenovirus vectors in cells which do not support virus replication (epithelial cells and fibroblasts), as this requirement is essential for gene therapy.
SV40, ␤ actin, human HCMV and Ad MLP promoters have been recently compared:
17 SV40 and ␤ actin promoters expressed poorly while HCMV and Ad MLP were best, functioning equally well but with different kinetics. We chose in this study to include another viral promoter, the MCMV which has been shown to have a wider range of host species cell types. 18 In vitro studies Northern blot analysis: Expression of elafin mRNA was assessed by Northern blot analysis in A549 epithelial cells, human and rat fibroblasts after Ad5-HCMV-EL, -MLP-EL and -MCMV-EL infection (see Figure 1 for the construction of Ad5-MCMV-EL). The adenovirus control Ad5-dl70/3 did not induce any endogenous elafin mRNA in any of the cells studied ( Figure 2a , b and c; upper panels). As shown in Figure 2 , considerably more elafin message was driven from the MCMV promoter than from the other promoters in all three cell lines. As low a multiplicity of infection (MOI) as 0.5 was able to induce significant production of elafin message in A549 cells (Figure 2a upper panel) , human fibroblasts ( Figure 2b ) and rat fibroblasts (Figure 2c ). Ad5-MLP-EL produced no detectable levels of elafin mRNA in any of the cells studied (even at a MOI of 20) whereas Ad5-HCMV-EL produced detectable levels in A549 and lung fibroblasts only at a MOI of 20 (Figure 2a and 2b ; upper panels) and not at a lower MOI (not shown).
The MCMV promoter was the only effective promoter in rat fibroblasts (Figure 2c ; upper panel).
Production of HCMV-EL, MLP-EL and MCMV-EL as assessed by ELISA: Consistent with Northern blot analysis data, the MCMV promoter was by far the strongest promoter driving expression of elafin and leading to significant transgene protein secretion in all cells studied (Table 1) . No detectable amounts of elafin were measured in nontransfected cells (not shown). Considerably less elafin protein was recovered using the HCMV or MLP constructs in A549 cells, rat and human fibroblasts.
Biological activity of elafin after Ad5-MCMV-EL infection of A549 cells: The anti-elastase activity of adenovirusderived elafin was assessed as explained in Materials and methods after infecting A549 cells in serum-free medium. The most efficient construct MCMV-EL (see Figure 2 and Table 1 ) was chosen for this study. Figure 3 shows that conditioned medium from A549 cells infected with Ad5-MCMV-EL (50 MOI) inhibits human neutrophil elastase (HNE) in a dose-dependent fashion (Figure 3; circles) . Extrapolation of the curve to the X axis shows that about 15 l of medium can inhibit 100 ng of HNE. In contrast, conditioned medium obtained from cells infected with the control virus Ad5-dl70/3 did not exhibit any anti-HNE activity (Figure 3 ; triangles).
In vivo studies
Increasing doses of Ad5-dl70/3, Ad5-HCMV-EL and Ad5-MCMV-EL were administered intra-tracheally in Sprague-Dawley rats to determine whether the spectrum of activity of the different promoters was similar in vivo to that previously observed in vitro. Specific elafin mRNA and protein were measured by Northern blot analysis and ELISA.
Northern blot analysis: No elafin mRNA expression was detected in the lung after infection with Ad5-HCMV-EL or Ad5-MLP (data not shown). In contrast, delivery of Ad5-MCMV-EL led to significant expression of elafin mRNA in the lung. Figure 4 shows that 2 days after infection, one animal infected with 10 9 p.f.u. showed significant levels of mRNA (lane 4). However, 5 days after infection, elafin mRNA was present in high quantities in the lungs from all animals (infected with 3 × 10 8 , 10
9 and 3 × 10 9 p.f.u., lanes 5-7), whereas 10 days after infection, mRNA levels were markedly decreased in two animals infected with 3 × 10 8 p.f.u. (lanes 9 and 10). By contrast, lungs of animals infected with equivalent doses of a nonrelevant virus (dl70/3) did not induce any detectable level of elafin mRNA ( Figure 4 , lanes 2, 3 and 8).
Elafin protein levels in bronchoalveolar lavage (BAL) from rats infected with Ad5-dl70/3, Ad5-HCMV-EL, Ad5-MLP-EL and Ad5-MCMV-EL: BAL recovered after 2, 5 and 10 days of infection were assessed for the presence of elafin by ELISA ( Figure 5 ). Whereas Ad5-dl70/3, -HCMV-EL and -MLP-EL infections did not result in significant production of elafin (below the level of detection, ie 0.3 ng/ml), Ad5-MCMV-EL infection was effective and peak expression of protein was seen at day 5. At day 10, protein levels were back to being undetectable, in keeping with Northern blot analysis ( Figure 4 ).
Discussion
Antiproteinase intervention is increasingly envisaged as a potential way to control lung inflammation in such diseases as emphysema or cystic fibrosis. 19 So far, emphasis has been placed on alpha-1 proteinase inhibitor (alpha1Pi) in this context since plasma deficiency of this elastase inhibitor has been identified in association with the development of emphysema in patients homozygous for the alpha-1Pi gene mutation (ZZ). 20 Clinical trials are currently underway using an alpha-1 Pi gene transfer approach in ZZ and cystic fibrosis patients. 21 Although this strategy is entirely logical in correcting hereditary lack of alpha-1Pi, there is much controversy regarding the role of alpha-1Pi in the development of emphysema in smokers with apparently normal genes for alpha-1Pi. To our knowledge, alpha-1Pi is the only elastase inhibitor of potential use in these diseases which has been engineered for gene therapy. 6 However, other inhibitors of lower molecular weight could potentially be used advantageously. Secretory leukocyte proteinase inhibitor (SLPI) is an important low molecular weight molecule which has been isolated in bronchial secretions. 22, 23 In addition, elafin is a newly discovered low molecular weight elastase inhibitor found in bronchial secretions and in the skin of psoriatic patients. 12, 15, 16, 24 The N-terminus of the molecule contains
Figure 1 Construction of adenovirus-MCMV-EL. A 554 bp fragment containing the endogenous leader and polyA sequences was ligated into a shuttle vector (PDK6) containing adenovirus sequences (0-1 map unit (mu) and 9.8-15.8 mu and deleted of the E1 region which is essential for virus replication) and the mouse cytomegalovirus promoter (MCMV). The resulting vector (pDK6-ELAFIN) was cotransfected in 293 cells with pBHG10, a plasmid containing the entire adenovirus gene sequence aside from 0.5-3.7 mu and 78-85.6 mu. Homologous recombination gave rise to an E1-deleted adenovirus containing the elafin cDNA, under the control of the MCMV promoter (Ad5-MCMV-EL).

Figure 2 Northern blot analysis of A549 cells (a), human lung fibroblasts (b) and rat lung fibroblasts (c) infected with Ad5-HCMV-EL, Ad5-MLP-EL, Ad5-MCMV-EL and Ad5-dl70/3 (control virus).
Cells were infected with Ad5 constructs at different MOI. After 48 h, RNA was prepared and 20 g of RNA was electrophoresed and blotted on to a Biotrans nylon membrane (see Materials and methods).
Upper Cells were infected with different MOI: 5, 10 and 20. Medium (5 ml) was recovered after 48 h and elafin protein was assayed by ELISA (expressed as ng/ml/24 h). Three independent experiments were performed (n = 3). ND, not detected.
Figure 3 Anti-human neutrophil elastase (HNE) activity of conditioned medium from A549 cells infected with Ad5-MCMV-EL (circles) or Ad5-dl70/3 (triangles). Increasing amounts of conditioned medium from Ad5-MCMV-EL or Ad5-dl70/3 infected A549 cells were incubated with purified HNE and assayed for anti-HNE activity (see Materials and methods). HNE activity was assessed using MeO-succinyl-alanine(2)-proline-valine-p-nitroanilide as substrate and the rate of change of absorbance was followed at 405 nm. HNE activity is expressed as percentage of control (HNE + alpha-MEM alone).
VKGQ repeating sequences which are involved in transglutamination reactions 16 resulting in 'anchoring' of the inhibitor to extracellular matrix proteins, presumably promoting a local protective role. The anti-elastase activity of elafin and its down-regulation in bronchial secretions from patients with chronic obstructive pulmonary diseases and cystic fibrosis 25 make it a particularly attractive candidate for gene therapy purposes in pathologies associated with elastolytic damage. Against this background, we engineered a series of adenovirus constructs expressing elafin cDNA. It is becoming increasingly evident that the levels of transgene product obtained in vitro and in vivo are highly dependent on the promoter used to drive synthesis. One of the objectives of this study was therefore to compare, both in vitro and in vivo, the levels of elafin secreted when under the control of the human cytomegalovirus (HCMV) promoter, a 373-bp fragment (−299 to +72 relative to transcriptional start 26 ), the adenovirus major late promoter (MLP) 27 and the mouse cytomegalovirus IE promoter (MCMV), a 1.4-kb (−1336 to +36) fragment of the pHind33 plasmid, a gift of U Koszinowski, University of Heidelberg, Germany. 28 Although the E3 deletions in pJM17 and pBHG10 are not completely identical (1.9 kb between 79.4 and 84.8 map units (mu) and 2.7 kb between 78.0 and 85.6, respectively), the outcome is similar in that it removes the major portion of all E3 messages. 29 In vitro experiments showed unambiguously that the MCMV promoter drives constitutively high levels of the elafin cDNA as assessed by mRNA and protein levels ( Figure 2 and Table 1 ). Interestingly, all cell types (human epithelial cells and both human and rodent fibroblasts) produced high amounts of MCMV-derived elafin mRNA and protein, whereas only human epithelial cells produced significant amounts of HCMV-derived elafin. Similarly, MLP was a poor promoter in all three cell types tested. HCMV promoter strength was intermediate between that of MCMV and MLP, except in rat fibroblasts where neither MLP nor HCMV elicited production of elafin mRNA or protein. These results highlight the observation that cells which cannot support replication of viruses (A549 cells and fibroblasts) exhibit differences in promoter efficiency as noticed previously by Xu et al. 17 For example, in keeping with Xu et al's study in Hela cells, we found that MLP was a poor promoter compared with HCMV in A549 cells ( Figure 2 and Table 1) .
Expression may also depend on the reporter gene itself since we found that in A549 cells, elafin expression is driven more efficiently by HCMV than MLP, a pattern different from that observed for the expression of VP7sc by Xu et al. 17 The biological activity of adenovirus-derived elafin was confirmed in that conditioned medium from A549 cells infected with Ad5-MCMV-EL inhibited HNE in a dose-dependent fashion (Figure 3) . Furthermore, biological activity of elafin was further demonstrated by the resistance of A549 cells transfected with Ad5-MCMV-EL to HNE-induced damage (unpublished data).
Interestingly, our in vivo data in Sprague-Dawley rats closely mirrored those obtained in vitro in rat fibroblasts. In animals treated with Ad5-HCMVor Ad5-MLP-EL, we were unable to detect significant levels of elafin mRNA or protein (Ͻ0.3 ng/ml) in total lung or BAL (Figures 4  and 5) . In contrast, Ad5-MCMV-EL gave rise to significant amounts of both elafin mRNA and protein, particularly at day 5 after infection. At day 10, levels were virtually back to background values. It is noteworthy that an infective dose as low as 3 × 10 8 p.f.u. gave maximal expression of both mRNA and protein. This is a relatively low dose of virus, when compared with other systems where a higher dose is required to obtain maximal expression. This may have important implications with respect to gene therapy where a system requiring low dosage of virus, and hence minimal inflammation, would be advantageous.
Low efficiency of Ad5-HCMV (373 bp)-derived expression of some cytokines has also been observed in 
Figure 4 Northern blot analysis of Sprague-Dawley rat lung tissue after infection with Ad5-MCMV-EL or Ad5-dl70/3 for 2, 5 or 10 days. After infection with various doses of Ad5 (p.f.u.), rat lungs were removed after either 2, 5 or 10 days. Lungs were snap frozen in liquid nitrogen and RNA was prepared. Forty micrograms of total RNA were electrophoresed and blotted on to a Biotrans nylon membrane (see Materials and methods
Figure 5 Elafin protein levels in BAL from Sprague-Dawley rats infected intratracheally with Ad5-dl70/3, Ad5-HCMV-EL, Ad5-MLP-EL and Ad5-MCMV-EL (see Figure 4). After infection with various doses of adenovirus (p.f.u.), rats were lavaged with sterile PBS after 2, 5 or 10 days. BAL fluid was centrifuged and supernatants were assessed for elafin protein by ELISA (see Materials and methods).
rodent lung in our laboratory (data not shown), suggesting that the low expression observed in lungs using this minimal HCMV is not confined to a particular transgene. In contrast, the 'large HCMV' (PAC-CMV) promoter, containing a 720-bp immunoglobulin enhancer 30 has been shown by us and others to be relatively efficient. 31, 32 In another animal species (cotton rat), the Ad2-MLP promoter was able to induce significant levels of human alpha-1Pi protein in lung lavage fluid. 6 The reason for our failure to detect MLP-driven elafin expression could be due to the use of a different enhancer (polyoma virus enhancer instead of the E1a enhancer in the previous study). Interestingly, the mouse cytomegalovirus promoter (MCMV) is efficient both in human and rodent systems. The strength of this particular promoter is probably due to the presence of the strongest gene enhancer (800 bp) isolated so far. 28 The choice of a strong promoter in gene transfer experiments is particularly important in order to achieve significant expression of the protein of interest in vivo. In vivo, it is also probable that the efficacy of particular promoters will depend upon the organ to which the transfer is targeted. We have found that MCMV is a strong promoter not only in the lung (this study) but also in other organs such as the stomach and the intestine studied in a mouse transgenic model (unpublished data).
In conclusion, we have designed a replication-deficient adenovirus expressing high levels of elafin under the control of the constitutive MCMV promoter. This promoter is active in both rodent and human cells and thus could be the promoter of choice for many gene transfer applications, such as the study of rodent models (we found that MCMV is also efficient in mice, unpublished data) as well as in 'therapeutic' gene transfer in humans.
Elafin is an elastase inhibitor which might have several advantages over other inhibitors such as alpha-1-Pi inhibitor and secretory leukocyte proteinase inhibitor. Its small size is an advantage in terms of diffusibility in inflamed areas, and its specificity for elastases could be beneficial in avoiding possible adverse effects. Furthermore, contrary to SLPI, elafin can inhibit proteinase-3, a potent neutrophilic enzyme 33 which has been shown to induce emphysematous lesions in hamsters. 34 Finally, this inhibitor possesses 'anchoring sequences' which might concentrate its activity locally in the interstitium, where most needed. Gene therapeutic augmentation of anti-elastases might have important implications in the near future for acute or chronic inflammatory diseases such as the adult respiratory distress syndrome, emphysema or cystic fibrosis. To this end, ongoing studies in our laboratory are examining the anti-inflammatory effect of human elafin on elastase-mediated lung inflammation in rodents.
Materials and methods
Molecular biology reagents
Reverse transcriptase (derived from Moloney virus) was derived from GIBCO (Gaithersburg, MD, USA). Taq polymerase was from Perkin-Elmer Cetus (Norwalk, CT, USA). Restriction endonucleases were obtained from NEN Biolab (Mississauga, Canada).
The human elafin cDNA probe was a 538-bp BamHIEcoRI elafin cDNA fragment (see below). The human ␤ actin probe was a 600-bp BamHI-EcoRI cDNA fragment in PGEM 3Z+ plasmid.
Recombinant elafin
Recombinant elafin (expressed in yeast) was a generous gift from Dr J Fitton (Zeneca Pharmaceuticals, Macclesfield, UK). The protein was dissolved in phosphate-buffered saline (PBS) to a concentration of 5 mg/ml.
Oligonucleotides
Oligonucleotides were synthesized by the Central Facility of the Institute for Molecular Biology and Biotechnology, McMaster University.
(1) 5′ CGGGATCCCGACACCATGAGGGCCAGCAGC-TTCTTG 3′ (2) 5′ GGAATTCCTTTATTGGAAAGTGGATGAGAGA-GGCAGCTC 3′
Oligonucleotide primers 1 and 2 were designed from the sequence of the elafin gene 13 and were chosen to be complementary to regions in exons 1 and 2, respectively. Oligonucleotide 1 is composed (from 5′ to 3′) of a BamHI site (underlined), to facilitate further sub-cloning of the PCR-generated cDNA), the Kozak's sequence and the first 21 nucleotides of the coding region. Oligonucleotide 2 is composed (from 5′ to 3′) of an EcoRI site (underlined), for sub-cloning, followed by the elafin polyA signal and the 25 nucleotides preceding the signal.
Adenovirus constructs
Construction of elafin cDNA: The only initially available elafin cDNA (gift from Drs Pioli and Tonge, Zeneca Pharmaceuticals) was a truncated form of the full-length molecule. 13 This cDNA coded for aminoacids 61-117 of the total protein. The full-length elafin cDNA was constructed by RT-PCR, from total RNA extracted from NCI-H322 cells, a bronchial epithelial cell line expressing the elafin gene. 13, 14 Five micrograms of total RNA were reverse-transcribed with 0.2 mm dNTPs (final concentration), 1 g of primer 2 and 2 l of MMLV reverse transcriptase in a final volume of 20 l. After incubation at 42°C for 40 min, 10 l was submitted to the polymerase chain reaction (PCR, using 0.25 mm dNTPs (final concentration), 1 g of primer 1 and 0.5 l of Taq polymerase in a final volume of 100 l. Forty cycles of amplification were carried out in a thermal cycler (Perkin-Elmer Cetus), using the following conditions for each cycle: 1 min at 95°C, 2 min at 55°C and 2 min at 72°C. Amplification products were then analyzed on 0.8% agarose gels. The amplification product was cut from the agarose gel, purified using GeneClean (Stratagene, La Jolla, CA, USA) and ligated by conventional methods into the polylinker sites of the different shuttle plasmids (see below). To control for unwanted PCR-induced mutagenesis, we checked the sequence of the pre-elafin cDNA obtained with the native cDNA.
14 Double stranded DNA (538 bp) sequencing was performed in house by the McMaster facility (Mobix). Three different primers were used and no mutagenesis was found (data not shown).
Construction of Ad5-HCMV-EL:
The BamHI-EcoRI cDNA elafin fragment (538 bp, see above) was cloned into the polylinker site of pHCMVsp14, a plasmid containing the human cytomegalovirus promoter (380 bp) and the sequences between 0 and 340 bp (0-1 mu) and between 3528 and 5688 bp (9.8-16 mu) of the Ad5 genome (E1 deleted). The resulting plasmid was called p-HCMV14-EL. This plasmid was used to rescue the elafin cDNA into the adenovirus genome by cotransfection of 293 cells with pJM17 which contains an ampicillin resistance gene, a bacterial origin of replication, an insert at 3.7 mu of a 4.4 kb fragment, which makes it too large to be packaged into infectious virions and a 1.9 kb deletion in the E3 region. Ad5-HCMV-EL was obtained by homologous recombination between the two plasmids. The presence of the correctly inserted elafin cDNA in the viral genome was checked by HindIII (H) digestion followed by Southern blot analysis (not shown).
Construction of Ad5-MLP-EL:
The BamHI-EcoRI elafin cDNA fragment (see above) was cloned into the polylinker site of psp1A, a plasmid containing the polyoma virus enhancer linked to the Ad2 MLP, the tripartite leader sequences and Ad5 sequences from 0 to 1 and 9.8 to 16 mu (E1 deleted, as above). This plasmid, constructed in our laboratory and designated pMLP-EL, was used to rescue the elafin cDNA in the adenovirus genome by cotransfection of 293 cells with pBHG10, 31 an E1-E3-deleted plasmid lacking the encapsidation signal (bp 194-358) and containing Ad5 sequences from bp 19 (left genomic end) to bp 188, bp 1339-28133 and bp 30818-35934. A segment of pBR322 is present in pBHG10 between bp 188 and 1339 to allow propagation in E. coli. As above, only homologous recombination (not shown) between pMLP-EL and pBHG10 gave rise to viable adenovirus particles in 293 cells. Southern blot analysis showed the correct insertion of elafin cDNA in the Ad5 genome (not shown).
Construction of Ad5-MCMV-EL:
The BamHI-EcoRI elafin cDNA fragment was digested from pMLP-EL (see above), ligated into the polylinker site of PGEM 3Z+ (Promega, Madison, WI, USA), and redigested with BamHI and SalI restriction enzymes. This 540-bp fragment was then ligated into pDK6, a derivative of pMHC5 29 which contains the MCMV promoter (1.8 kb), a polyadenylation signal and Ad5 sequences from 0 to 1 and 9.8 to 16 mu. The resulting plasmid was called pMCMV-EL and was used to rescue the elafin cDNA in the adenovirus genome by cotransfection of 293 cells with pBHG10 (see Figure 1) . A 500-bp elafin HindIII fragment was observed by Southern blot analysis (not shown).
Construction of Ad5-dl70/3: The control virus Ad5-dl70/3, which does not contain any foreign cDNA inserted into its genome was constructed and characterized as previously described. 29 Similarly to the other Ad5 described above, this virus had its E1 region deleted (3.2-kb deletion), making it incapable of replication.
Amplification and purification of adenoviruses: The above viruses were amplified, purified and titrated in 293 cells as previously described. 35 Briefly, two rounds of CsCl gradient centrifugation were used to purify the viruses. The viruses were further desalted by gel permeation chromatography, using PD-10 Sephadex columns (Pharmacia Biotech, Baie d'Urfe, Quebec, Canada). The virus fractions were collected in PBS containing 10% glycerol, measured for conductance, pooled, titrated to quantify number of p.f.u., aliquoted and stored at −70°C until further use.
Infection of A549 alveolar epithelial cells, human and rat primary pulmonary fibroblasts A549 epithelial cells (derived from a type II alveolar cell carcinoma) 36 and human and rat primary fibroblasts 37 were infected at confluency in 60 mm dishes (Falcon) with banded Ad5 (HCMV-EL, MLP-EL and MCMV-EL and dl-70/3 virus) at a MOI between 0.5 and 100. After 30 min in alpha-MEM supplemented with 5% FBS, medium was changed and cells were cultured with 5 ml of medium supplemented with 2% FBS. After 48 h, medium was collected and UV inactivated. The cell layer was treated with 0.5 ml of GITC, and RNA was prepared according to Chirgwin et al. 38 The presence of elafin RNA and protein was determined by Northern blot and ELISA, respectively.
Cell viability was assessed after each experiment by trypan blue exclusion and was found to be greater than 90% in all cases.
Anti-HNE activity of elafin produced by Ad-5-MCMV-EL A549 cells were infected as above with either Ad5-dl70/3 or Ad5-MCMV-EL (MOI of 50 in each case) in 24-well cell culture plates (Falcon, Becton Dickinson, NJ, USA). However, after infection, cells were extensively washed with PBS and cultured for a further 48 h in serum-free alpha-MEM medium to eliminate any interference from proteinase inhibitors contained in serum. Conditioned medium was UV inactivated and increasing amounts were then incubated for 30 min at 37°C with 10 l of PBS containing 100 ng of purified HNE (Elastin Products Company, Owensville, MO, USA) in 0.1 m Tris, 0.5 m NaCl, 0.1% Triton X-100, pH 8.0 (final volume 50 l). The control consisted of HNE incubated with alpha-MEM medium alone. The 50 l mixture was then transferred to a microtiter plate (Sero-Wel, Bibby Sterilin Ltd, Stone, UK) containing the HNE substrate MeO-succinylalanine(2)-proline-valine-p-nitroanilide (Sigma, St Louis, MO, USA), dissolved in the same Tris buffer containing 1% DMSO (final concentrations in the well 50 g/ml). Hydrolysis was recorded by monitoring the increase of absorbance at 405 nm for 15 min. In the absence of inhibitors, the enzyme had a specific activity of 10 000 units per mg of protein, as calculated according to the manufacturer's criteria.
Immunological detection of elafin protein
The amount of elafin was measured by an indirect ELISA assay, described and validated elsewhere, 39 using recombinant (r)-elafin as standard.
In vivo administration of adenoviruses Administration of virus (3 × 10 8 to 3 × 10 9 p.f.u. in 0.3 ml of sterile PBS) was performed intratracheally in male Sprague-Dawley rats as described elsewhere. 40 Three time-points were studied for each adenovirus construct (Ad5-HCMV-EL, Ad5-MLP-EL and Ad5-MCMV-EL): 2 days, 5 days and 10 days. Bronchoalveolar lavage was performed as previously described. 41 Typically, 30 ml of sterile PBS were injected in 5 ml aliquots. Recovery was typically 50-70%. Two aliquots were obtained containing 3 ml and 20 ml, respectively. Tubes were centrifuged to separate the supernatant from the cells. Only the supernatant from the 3 ml aliquot was used for further protein analysis. Simultaneously, lungs were removed; the left lung was cut into small pieces and snap frozen before RNA preparation.
Northern blot analysis
Confluent cells in 60-mm dishes were treated in situ with 0.5 ml of GITC whereas 0.5 g of lung tissue (snap frozen) was treated with 2.5 ml of GITC and homogenized. After RNA purification (as described above), 20 or 40 g of total RNA was electrophoresed as previously described. 14 Briefly, after transfer on to a Biotrans nylon membrane (ICN, Irvine, CA, USA), membranes were hybridised overnight at 55°C in 50 mm Pipes, 100 mm NaCl, 50 mm NaH 2 PO 4 , 1 mm EDTA, 5% SDS, pH 6.8 with 10 6 c.p.m./ml of labeled elafin cDNA probe or ␤ actin probe (after stripping of the original membrane). After hybridisation, filters were washed at 55°C for 1 h in 1 × SSC (150 mm NaCl, 15 mm sodium citrate, pH 7.0) containing 0.1% SDS and exposed for autoradiography.
